Market entry & go-to-market strategy

Building evidence-based pathways for successful therapy launches

At SouthBridge Advisory, we design and execute market entry strategies that balance affordability with commercial viability, ensuring advanced therapies reach patients in emerging markets faster and more sustainably. With a proven record of successful launches across 10+ markets, our approach blends real-world insights, hospital data, payer behavior, and KOL networks to deliver pragmatic results.

Our approach

Market landscaping & opportunity scan

Identifying therapy area gaps, competitor landscape, and pipeline positioning for optimal differentiation.

Access-driven go-to-market planning

Creating frameworks that integrate pricing, distribution channels, and patient access pathways.

Stakeholder engagement strategy

Mapping and engaging regulators, payers, physicians, and hospital networks to ensure early advocacy and adoption.

Launch readiness frameworks

Cross-functional planning across regulatory, medical, supply chain, and commercial teams to accelerate time-to-market.

why partner with us?

25+ years of hands-on global experience in advanced therapies commercialization.
End-to-end expertise from market entry planning to execution.
Proven success in navigating complex LMIC environments.
Advisory built on real-world outcomes, not just theoretical models.

Testimonial

People like us, officially

Trusted by biopharma leaders, medical experts, and investors worldwide for delivering real-world commercialization success in advanced therapies.

SouthBridge’s deep understanding of pricing and access challenges in emerging markets was instrumental in the successful launch of our biologic. Their execution-first approach set them apart from other consultants.

Biopharma Executive Emerging Markets

The team at SouthBridge bridged the gap between science and market strategy. Their KOL engagement framework helped us build strong advocacy and accelerate adoption of our cell therapy

Medical Affairs Director Global CGT Company

SouthBridge’s due diligence and market insights gave us the confidence to invest in a groundbreaking gene therapy. Their practical expertise ensured we had a clear roadmap for commercialization.

Investor Healthcare VC Fund